Cornell University researchers developed machine-learning models that can sift through cell-free RNA and identify key biomarkers for myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS). The approach could lead to the development of diagnostic testing for a debilitating disease that has proved challenging to confirm in patients because its symptoms can be easily confused with those of other illnesses.

Portland State University researchers have released the final findings in a three-year project examining the impacts of multiple drug policy shifts including Measure 110 which decriminalized drug possession in Oregon. 

The final report finds little evidence that Measure 110 was responsible for rising crime or overdose deaths. Instead, researchers found that trends in crime rates and overdose fatalities were primarily driven by the COVID-19 pandemic and the rise of fentanyl. The report also offers crucial insights for the implementation of the state’s new drug policy (HB 4002), emphasizing that policy change alone isn't enough — successful deflection to treatment depends on robust resources and coordination.

Lipid nanoparticles (LNPs) are tiny fat bubbles that are used to deliver medicines, genes, and RNA into cells. However, in some cases LNPs can cause harmful inflammation as a result of the process of RNA delivery. Now, two new solutions can help alleviate inflammation while still getting RNA where it needs to be in the cell. One discovery found that inflammation could be reduced with the addition of a unique biodegradable lipid to the treatment; another solution identified a common drug, called thiodigalactoside (TG), which blocked inflammation when added to the LNP. Today’s Nature Nanotechnology features this research from the Perelman School of Medicine at the University of Pennsylvania.